Delving into Finnish Pharmaceutical Research and Development

"I’m inspired by our input in research and product development. For example, great opportunities may be presented by biologic drugs, which are being developed extensively around the world", says Christer Nordstedt.

"I have become familiar with Finland and Finns during my first year at Orion. I’m amazed at how easy it is to get along with my new colleagues and neighbours here", Nordstedt says.

Finns are also interesting as a research subject. Orion will also begin research into rare diseases, and we will be focusing on a group 36 Finnish heritage diseases. These diseases are more common in Finland than elsewhere in the world. This northern land remained isolated for a long time, which is why Finns continue to be a highly homogenous people. The genetic errors brought here by the first settlers are still present.

Researchers have also been inspired by their own heritage diseases. Finland has both genetics experts and highly advanced technology. Material collected about heritage diseases has been stored, and it is valuable in terms of developing new treatments.

I’m inspired by our input in research and product development. For example, great opportunities may be presented by biologic drugs, which are being developed extensively around the world. New research projects also mean we can offer more new jobs in Finland.

Christer Nordstedt is Senior Vice President, Pharmaceutical Research and Development at Orion.

Cooperation is incredibly important for us, as we are a relatively small player internationally. But it is also important for other operators. Not even major pharmaceutical companies can prepare all of their required ingredients themselves any longer. Orion supplies active pharmaceutical ingredients, such as methotrexate and mercaptopurin, from Hanko to elsewhere in the world.

Our international partners provide us with additional capacity for research and marketing. We need their contribution for many reasons, including the fact that our research areas – neurological diseases and cancer – are very demanding. Together with our partners, we are seeking treatments for ALS and other diseases, and the research on the darolutamide molecule in the treatment of prostate cancer has, in co-operation with Bayer, reached the final clinical stage.

My first year at Orion has meant learning a lot, and it has been a steep learning curve. At the same time, after having spent several years in the United States, I have admired the familiar unpolluted nature and Finns’ excellent language skills. I’m looking forward to my coming years here, among inspiring people.”

 

Christer Nordstedt, SVP, Pharmaceutical Research and Development at Orion

6 October 2017

Keywords: